Furthermore, a randomized cross-over study in 19 patients with MASH and 19 patients with simple fatty liver steatosis highlighted higher NOX2 activity and isoprostanes levels with a significant gradient between fatty liver steatosis and MASH. Here, CYBB is linked to metabolic dysfunction-associated steatohepatitis.